Biocon
Biocon Limited, established in 1978 and headquartered in Bengaluru, India, is a fully integrated biopharmaceutical company. It specializes in the development, manufacturing, and commercialization of a wide range of biopharmaceuticals, including biosimilars, novel biologics, and complex small molecule APIs. Biocon's portfolio spans recombinant human insulin, insulin analogs, monoclonal antibodies, and therapeutic proteins, targeting areas like diabetes, oncology, and immunology. The company operates through four segments: Biosimilars, Generics, Novel Biologics, and Research Services. It also offers contract research and manufacturing services to the pharmaceutical industry through its subsidiary, Syngene. Biocon's mission is to expand patient access to affordable, high-quality biopharmaceuticals, driven by a commitment to innovation and humanitarian responsibility.
Viatris Biosimilars
Acquisition in 2021
Viatris Biosimilars is focused on the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology.
Fusion Microfinance
Series D in 2016
Fusion Microfinance, headquartered in New Delhi, operates primarily in the North Central region of India, including Madhya Pradesh, Uttarakhand, Uttar Pradesh, Delhi, and Haryana. Established in January 2010, the company initially focused on microfinance lending to financially underserved women organized into Joint Liability Groups (JLGs). It provides small, collateral-free loans to empower these women and also extends its services to micro, small, and medium enterprises (MSMEs). In addition to lending, Fusion Microfinance leverages its distribution channels to offer various financial products aimed at enhancing productivity, such as loans for purchasing mobile handsets and bicycles. The company's acquisition of the microfinance division Aajeevika, which had a modest initial member base, further strengthened its operations and outreach in the sector.
Glympse Bio
Seed Round in 2015
Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.